Company

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea
and vomiting (OINV).
read more

Product PortfolioClinical TrialsPartners
CL-108, is currently being prepared for evaluation in an 1,100-patient Phase III clinical trial at investigative sites throughout the US, including major research universities in the US.

Recent News

November 2, 2010 - Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project Grant

May 18, 2009 - Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108

April 28, 2009 - Charleston Laboratories, Inc. Appoints Kerry Segal Chief Business Development Advisor

Feburary 12, 2009 - Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire

February 2, 2009 - Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ)
Charleston Lab's Solution to an Unmet Need
Approximately 75% of patients experience pain after surgery and current first line treatments utilize opioid analgesics. Opioids are known to cause nausea and vomiting (OINV) in conservatively 30-40% of the patient population. Charleston Labs' leading drug candidate, CL-108, and product portfolio provide pain relief and alleviate or eliminate side effects such as nausea and vomiting in patients who are prescribed opioids for moderate to severe pain, such as patients who experience pain after surgery.
For Investment Opportunity in Charleston Laboratories...
Product Portfolio   |   Clinical Trials   |   Terms of use   |   Privacy Policy